NCT01703286View on ClinicalTrials.gov

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo matching Glimepiride

DRUG

Linagliptin

given once daily for 28 days

DRUG

Placebo

Placebo matching Linagliptin

DRUG

Placebo

Placebo matching Linagliptin

DRUG

Placebo

Placebo matching Glimepiride

DRUG

Glimepiride

1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)

Trial Locations (1)

Unknown

1218.105.001 Boehringer Ingelheim Investigational Site, Neuss

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY